CD19-directed chimeric antigen receptor (CAR) T-cell therapy has been widely used and highly effective for B-cell lymphoid malignancies. Immune-mediated adverse effects such as cytokine release syndro
Purpose: To compare cell states amoung three populations of interest among circulating CAR T cells in patients with lymphoma. Methods: Nine patients with large B-cell lymphoma (LBCL) were treated with
Chimeric antigen receptor (CAR) T cells mediate potent antigen-specific antitumor activity, however, their indirect effects on the endogenous immune system is not well characterized. Remarkably, we de
